Patients with chronic kidney disease–mineral and bone disorder (CKD-MBD) frequently have low bone formation rates. A recent review suggested that adynamic bone disease is not always associated with negative outcomes and therefore antiresorptive medications could be used more often. However, there is currently no evidence to support an improvement in fracture risk or mortality in patients with CKD-MBD and low bone turnover who are treated with antiresorptive medication. There is reasonable pathophysiological evidence suggesting that it may even be harmful.

中文翻译：

---

骨转换对 CKD-MBD 患者治疗决策的重要性

慢性肾病-矿物质和骨骼疾病 (CKD-MBD) 患者的骨形成率通常较低。最近的一项综述表明，无动力性骨病并不总是与负面结果相关，因此可以更频繁地使用抗吸收药物。然而，目前没有证据支持接受抗吸收药物治疗的 CKD-MBD 和低骨转换患者的骨折风险或死亡率有所改善。有合理的病理生理学证据表明它甚至可能有害。